The Duke of Cambridge visits the University of Oxford\u2019s Oxford Vaccine Centre, to learn more about their work to establish a viable vaccine against COVID-19.
AstraZeneca has reached an agreement with Europe\u2019s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford\u2019s COVID-19 vaccine, with deliveries starting by the end of 2020.
Bristol Science Film Festival awarded the Professional Science Fact Film Prize to \"The Adventures of Alice in Typhoidland\" co-created by the Oxford Vaccine Group.
The Academy of Medical Sciences, the independent body in the UK representing the diversity of medical science, has announced the election of fifty new Fellows, including Professor Matthew Wood from the Department of Paediatrics.
How can researching a cohort of infants from KwaZulu-Natal in South Africa help explain differing HIV susceptibility of males and females? Professor Philip Goulder, head of the HIV Research Group, discusses the Baby Cure study.
The University of Oxford has today announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the Oxford Vaccine Group.
University of Oxford researchers have begun testing a COVID-19 vaccine in human volunteers in Oxford today. Around 1,110 people will take part in the trial, half receiving the vaccine and the other half (the control group) receiving a widely available meningitis vaccine.
A multi-site project, called \u2018What\u2019s the STORY?\u2019 has received funding from UK Research and Innovation (UKRI) to assess novel coronavirus infection rates in children and teenagers across the UK. Given the importance of this study to the national Covid-19 response it has been deemed a priority study for the National Institute for Health Research\u2019s (NIHR) Urgent Public Health Response.
Five projects from across Oxford University's Medical Sciences Division, including a project led by Professor Matthew Snape from the Oxford Vaccine Group, are among twenty-one new studies into the novel coronavirus which have been funded by the UK government.
University of Oxford researchers working in an unprecedented vaccine development effort to prevent COVID-19 have started screening healthy volunteers (aged 18-55) today for their upcoming ChAdOx1 nCoV-19 vaccine trial in the Thames Valley Region. The vaccine based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein is already in production but won\u2019t be ready for some weeks still.
At the beginning of the year our family leave policies were updated. Employees can now take up most of our family leave schemes from the first day of employment, meaning that more parents can now enjoy the benefits of our generous provisions. Hayriye Cagnan from the Nuffield Department of Clinical Neurosciences, and husband Eugene Duff from the Department of Paediatrics, discuss their experience of shared parental leave following baby Ida\u2019s arrival ten months ago.
Wood Group researchers in the Department of Paediatrics collaborate with DPAG's Denis Noble to produce innovative podcast talks on a prominent global platform, the Future Tech Podcast. Following the release of the final podcast talk in February 2020, we chart the story leading to these innovative pieces of public engagement.
A new exhibition tells the story of Oxford\u2019s role in the fight against typhoid, from pioneering efforts to eliminate typhoid in the era of Lewis Carroll\u2019s Alice in Wonderland to game-changing present-day vaccine trials
FUNDING ALERT: The Harrington Discovery Institute are welcoming proposals to advance innovative research in the rare disease space. Deadline: Monday 2 March
Work will shortly be underway on the new IMS-Tetsuya Nakamura Building, home to the new Institute of Developmental and Regenerative Medicine at Old Road Campus. The formal ground-breaking ceremony, which took place towards the end of last year, was organised by the Department of Paediatrics in collaboration with the Medical Sciences Development team.
A large field study of typhoid conjugate vaccine (TCV) in Nepal has shown a single dose to be safe and effective in reducing typhoid in children aged 9 months to <16 years in an endemic setting.
![\"Duke](\"https://www.paediatrics.ox.ac.uk/news/the-duke-of-cambridge-visits-oxford-vaccine-centre/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n